If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information.
For more information on upper gastrointestinal cancer clinical trials, get in contact with our Monc B team This email address is being protected from spambots. You need JavaScript enabled to view it..
Open and Recruiting Clinical Trials
D7988C00001 / eVOLVE-Meso
A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma.
Trial ID
NCT06097728
Cancer type
Mesothelioma
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
BO43249 / Horizon-02
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status
Trial ID
NCT06624059
Cancer type
Prostate cancer
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
BO44426 / Krascendo 170
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation.
Trial ID
NCT05789082
Cancer type
Lung cancer
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
D7632C00001 / TROPION-Lung10
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations.
Trial ID
NCT06357533
Cancer type
Lung cancer
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
ORIC-114-01
An Open-Label, Phase 1/2 Study of ORIC-114 As a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration.
Trial ID
NCT05315700
Cancer type
Lung cancer only
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
V940-002 / INTerpath-002
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II-IIIB (N2) Non-small Cell Lung Cancer.
Trial ID
NCT06077760
Cancer type
Non-small Cell Lung Cancer
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the the Australian Clinical Trials Registry.
DZ2022E0005 / WU-KONG28
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation.
Trial ID
NCT05668988
Cancer type
Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
Codebreak 202
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C.
Trial ID
NCT05920356
Cancer type
PD-L1-negative Non-Small Cell Lung Cancer with KRAS p.G12C Mutation
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
OCEANiC
A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Following Complete Surgical Resection.
Trial ID
ACTRN12623000552684
Cancer type
Non-Small Cell Lung Cancer
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
ALKOVE-1
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumours.
Trial ID
NCT05384626
Cancer type
ALK-positive Non-Small Cell Lung Cancer
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
PACIFIC-9
A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.
Trial ID
NCT05221840
Cancer type
Non-Small Cell Lung Cancer
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
BO42777
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts Of Patients Selected According to Biomarker status, with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer.
Trial ID
NCT05170204
Cancer type
Non-Small Cell Lung Cancer
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
BX43361
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
Trial ID
NCT05419375
Cancer type
Lung Cancer
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
ARROS-1
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors
Trial ID
NCT05118789
Cancer type
ROS1-positive Non-Small Cell Lung Cancer and Other Solid Cancers
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
CIAG933A12101
An open-label, multi-center, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors.
Trial ID
NCT04857372
Cancer type
Mesothelioma
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
Title
A Phase 1a\1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination with Pembrolizumab in Subjects with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer.
Trial ID
NCT06343402
Cancer type
Non-Small Cell Lung Cancer with KRAS G12C Mutation
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
Vivace
Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VT3989 in Patients with Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (mutant NF2 or mNF2).
Trial ID
NCT04665206
Cancer type
Mesothelioma
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trial Registry.
If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.
